| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/17/2013 | WO2013009981A2 Treating neurological disease or injury with a dynamin-related protein 1 (drp1) encoding nucleic acid |
| 01/17/2013 | WO2013009979A2 Compositions and methods for suppressing gene expression of p53 and clusterin |
| 01/17/2013 | WO2013008881A1 Ischemic disease therapeutic agent |
| 01/17/2013 | WO2012161539A3 Sirna for inhibiting the expression of bhrf1 and composition comprising same |
| 01/17/2013 | WO2012158866A9 Treatment of autoimmune disorders and infections using antagonists of sgk1 activity |
| 01/17/2013 | WO2012156839A3 Splice - less lentiviral vectors for safter gene therapy applications |
| 01/17/2013 | WO2012149566A3 Anti-hiv group i introns and a uses thereof in treating hiv infections |
| 01/17/2013 | WO2012149406A3 Assessing and treating humans with long qt syndrome |
| 01/17/2013 | WO2012149376A3 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| 01/17/2013 | WO2012145582A3 Methods and compositions for the specific inhibitions of egfr by double-stranded rna |
| 01/17/2013 | WO2012142083A3 C1q/tnf-related protein 12 and compositions and methods of using same |
| 01/17/2013 | WO2012135818A3 Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis |
| 01/17/2013 | WO2012071526A3 Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| 01/17/2013 | US20130018088 Methods and compositions for anti-egfr treatment |
| 01/17/2013 | US20130018087 miRNA Compounds for Treatment of Prostate Carcinoma |
| 01/17/2013 | US20130018085 iRNA Agents Targeting VEGF |
| 01/17/2013 | US20130017998 Novel modified galectin 9 proteins and use thereof |
| 01/17/2013 | US20130017179 Lineage-Restricted Neuronal Precursors |
| 01/17/2013 | CA2841451A1 Ischemic disease therapeutic agent |
| 01/16/2013 | EP2545941A1 Method for proliferating cardiomyocytes using micro-rna |
| 01/16/2013 | EP2545170A1 Death associated protein 1 variants and use thereof for modulating autophagy |
| 01/16/2013 | EP2544722A1 Method and composition for alveolar epithelial cell-specific nucleic acid nuclear import |
| 01/16/2013 | EP2544721A1 Non-aqueous high concentration reduced viscosity suspension formulations |
| 01/16/2013 | EP2544688A2 Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| 01/16/2013 | CN1454257B Production of recombinant blood clotting factors in human cell lines |
| 01/16/2013 | CN102884041A Cationic lipid |
| 01/16/2013 | CN102876778A Application of APP genes in preparing early definitive t(8;21)/AML1/ETO+AML prognostic preparation |
| 01/16/2013 | CN102876770A Tumor metastasis marker gene and application thereof |
| 01/16/2013 | CN102876716A Lentiviral expression vector for specifically promoting hepatic cell CYP2E1 gene high expression, construction method of vector and application of vector |
| 01/16/2013 | CN102876715A Retroviral vector for gene therapy for tuberculosis and HIV (Human Immunodeficiency Virus) coinfection and application thereof |
| 01/16/2013 | CN102876697A Nano cationic liposome carrying FL gene recombinant plastid, and preparation method and application of nano cationic liposome |
| 01/16/2013 | CN102876696A Preparation method and application of tissue in situ high-expression ILK (integrin linked kinase) protein carrier |
| 01/16/2013 | CN102876682A Schistosoma Japonicum polymorphism antigen gene and application thereof as vaccine |
| 01/16/2013 | CN102876675A Peptide nucleic acid for subgroup J avian leukosis viruses and application of peptide nucleic acid |
| 01/16/2013 | CN102876666A RNA body and its application |
| 01/16/2013 | CN102875684A FGFR single-stranded antibody fusion protein and application thereof in preparing targeting tumor cells medicines |
| 01/16/2013 | CN102875667A HIV-1 (human immunodeficiency virus-1) peptide Env120-128 specificity TCR (T cell receptor), recombinant retroviral vector thereof and application |
| 01/16/2013 | CN102875666A Tuberculosis antigen specificity TCR (T cell receptor), recombinant retroviral vector thereof and application |
| 01/16/2013 | CN102875647A Ligand polypeptide and medicine transferring system combined with specificity of CD40L protein |
| 01/16/2013 | CN102872464A Novel choroidal neovascularization gene therapeutic medicine and use thereof |
| 01/16/2013 | CN102872463A Nanoparticles comprising rna ligands |
| 01/16/2013 | CN102872459A Cell factor IL-16 and application of PepT1 expression regulated and controlled by cell factor IL-16 |
| 01/16/2013 | CN102872456A One dose vaccination with mycoplasma hyopneumoniae |
| 01/16/2013 | CN102234645B Artificially synthesized promoter for gene therapy and vaccine development |
| 01/16/2013 | CN102210867B pH reversible response mesoporous silicon oxide composite medicament-carrying system, preparation method thereof and application thereof |
| 01/16/2013 | CN102133404B Tumor targeted therapeutic drug carrier as well as preparation method and application thereof |
| 01/16/2013 | CN102102102B Novel application of hsa-miR-185 |
| 01/16/2013 | CN102041256B Human miR-486-5p antisense nucleic acid and application thereof |
| 01/16/2013 | CN101948858B RNA (Ribose Nucleic Acid) interference recombination vector of SET (Patient SE Translocation) genes and establishment method and application thereof |
| 01/16/2013 | CN101948543B Fusion protein and coding gene and application thereof |
| 01/16/2013 | CN101024845B Use of nucleotide sequence for encoding protein of gag and pol, method for producing replication-defective retrovirus |
| 01/15/2013 | US8354524 Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids |
| 01/15/2013 | US8354522 Immunostimulatory oligoribonucleotides |
| 01/15/2013 | US8354393 Film preparation and process for preparing the same |
| 01/15/2013 | US8354388 Inhibitors of MRP4 for the treatment of vascular disorders |
| 01/15/2013 | US8354387 Methods and compositions for delivering siRNA into mammalian cells |
| 01/15/2013 | US8354386 Pharmaceutical composition for treating malignant tumors containing human p31 genes |
| 01/15/2013 | US8354385 Modulation of TRPV expression levels |
| 01/15/2013 | CA2583375C Regulation of oncogenes by micrornas |
| 01/15/2013 | CA2460269C Alphavirus replicon vector systems |
| 01/15/2013 | CA2451864C Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| 01/15/2013 | CA2443323C Nucleic acid vaccines for prevention of flavivirus infection |
| 01/15/2013 | CA2400842C Novel compounds |
| 01/10/2013 | WO2013006841A1 Stimulation of arterial collateral growth and lymphogenesis |
| 01/10/2013 | WO2013006763A1 Oral delivery of enzymes by nanocapsules for targeted metabolism of alcohol or toxic metabolites |
| 01/10/2013 | WO2013006629A1 Methods and compositions for assigning likelihood of acute kidney injury progression |
| 01/10/2013 | WO2013006558A2 Compositions and methods for treating skeletal myopathy |
| 01/10/2013 | WO2013006514A2 Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases |
| 01/10/2013 | WO2013006436A1 Acsf3 mutations in metabolic disorders |
| 01/10/2013 | WO2013006230A2 Combined inhibition of the vitamin d receptor and dna replication in the treatment of cancer |
| 01/10/2013 | WO2013003987A1 Tumor-targeted tumor necrosis factor-related apoptosis ligand variant and use thereof |
| 01/10/2013 | WO2013003887A1 Nucleic acid complex |
| 01/10/2013 | WO2012159006A8 Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof |
| 01/10/2013 | WO2012151575A3 A method of controlling coagulation |
| 01/10/2013 | WO2012149416A3 Human myeloid derived suppressor cell cancer markers |
| 01/10/2013 | WO2012142476A3 Methods and compositions for the treatment of marfan syndrome and associated disorders |
| 01/10/2013 | WO2012134135A3 Spermine copolymer and gene therapy using the spermine copolymer as a nucleic-acid carrier |
| 01/10/2013 | WO2012018115A9 Composition for regenerating normal tissue from fibrotic tissue |
| 01/10/2013 | US20130012573 Methods for intracellular delivery of nucleic acids |
| 01/10/2013 | US20130012570 GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION |
| 01/10/2013 | US20130012569 Method of treatments related to the fmr1 gene |
| 01/10/2013 | US20130012567 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/10/2013 | US20130012452 Method for treating brain cancer using a novel tumor suppressor gene and secreted factor |
| 01/10/2013 | US20130011903 Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities |
| 01/10/2013 | US20130011436 Methods and Compositions Containing Fc Fusion Proteins for Enhancing Immune Responses |
| 01/10/2013 | US20130011428 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/10/2013 | US20130011420 Antisense antiviral compounds and methods for treating a filovirus infection |
| 01/10/2013 | US20130011411 Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| 01/10/2013 | US20130011385 Transparent bacterial cellulose nanocomposite hydrogels |
| 01/10/2013 | US20130011380 Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming |
| 01/10/2013 | US20130011370 Uniform Field Magnetization and Targeting of Therapeutic Formulations |
| 01/10/2013 | US20130011367 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| 01/10/2013 | US20130011366 Therapeutic Agent for infections, and treatment method using the same |
| 01/10/2013 | CA2841376A1 N-terminal deleted gp120 immunogens |
| 01/10/2013 | CA2841079A1 Oral delivery of enzymes by nanocapsules for targeted metabolism of alcohol or toxic metabolites |
| 01/09/2013 | EP2543729A1 Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
| 01/09/2013 | EP2543659A1 Dendrimers as non-viral vehicles for gene therapy |
| 01/09/2013 | EP2542267A1 Inhibitory rnas to rna binding proteins hnrnpa1, hnrnpa2 and ptb and uses thereof |
| 01/09/2013 | EP2542266A1 Aptamers to 4-1bb and their use in treating diseases and disorders |
| 01/09/2013 | CN1446258B Purification of triple heli formation with immobilized oligonucleotide |